Indefinite recognition of CE marked devices in Great Britain: the October 2026 decision

1. Key takeaways

On 21 October 2026, the United Kingdom government confirmed that medical devices and IVDs CE marked under EU MDR (2017/745) and EU IVDR (2017/746) will receive long-term, indefinite recognition in the Great Britain market, with no separate mandatory UKCA conversion deadline being set. In parallel, the government will work to align the transitional arrangements for EU MDD compliant devices with the EU timetable. This is the most significant shift in British market access policy since the end of the transition period, and it changes the economics of serving Great Britain for every manufacturer holding MDR or IVDR certificates.

Three qualifiers attached to the decision must be understood together, not separately. First, legacy devices under MDD, AIMDD and IVDD are not covered by the indefinite recognition. Second, the three standing obligations, the UKRP, MHRA registration and PMS, are retained in full. Third, actual implementation still awaits secondary legislation, so the confirmation is a policy direction rather than an operative rule change. A manufacturer who reads only the headline and skips the qualifiers will build a plan that fails on all three points at once.

2. Legal basis

• GOV.UK / MHRA news announcement titled ‘Government confirms indefinite recognition of CE marked medical devices’, published on 21 October 2026.
• GOV.UK consultation response titled ‘Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices’: consultation ran from 16 February 2026 to 10 April 2026, the response was published on 21 October 2026, and 1,056 responses were received in total.
• Currently operative text: UK MDR 2002 (SI 2002/618, as amended), reg 1ZA, reg 19B, reg 19C, reg 30A, reg 44ZA and reg 44ZB.

3. Expert insights

Insight one: this is the removal of a deadline, not the removal of UKCA. The official announcement makes explicit that the UKCA route continues to operate as the domestic approval pathway for Great Britain and is being modernised through the proposed premarket statutory instrument. What changes is the position of UKCA in the decision tree: it moves from a future mandatory compliance task to an optional commercial and strategic choice. Manufacturers should therefore stop budgeting UKCA as an unavoidable fixed cost and start evaluating it as an investment with a case-by-case return, weighed against the alternative of continuing on CE certificates.

Insight two: the data reveals the realistic basis of the decision. The official announcement notes that more than 90 per cent of medical devices registered for use in Great Britain currently carry CE marking. In a market where nine in ten products depend on CE certificates, imposing a hard switching deadline would create supply chain risk far exceeding any regulatory benefit. That is the underlying logic of the policy choice, and it is also the reference point for judging the direction of the follow-up legislation: an instrument that forced rapid re-certification would contradict the very data that justified the confirmation, so a sudden reversal of direction appears unlikely.

Insight three: the three retained obligations are the consideration for long-term recognition. The government response states in terms that manufacturers placing CE marked devices on the Great Britain market must continue to comply with a number of domestic requirements, including appointment of a UK responsible person, MHRA registration and post-market surveillance (PMS) obligations, and that the MHRA continues to be responsible for monitoring the safety of all medical devices on the United Kingdom market. Indefinite recognition of CE marking does not reduce the British compliance burden. Budgets, staffing and vendor contracts built around those three obligations must continue without interruption.

Insight four: the third proposal was shelved. The proposal to create a separate international reliance route for devices whose classification in the United Kingdom sits higher than in the European Union did not attract majority support among respondents, on the view that the regulatory complexity it would introduce is disproportionate to the potential safety benefit. Its shelving is informative: it shows the government filtering reliance concepts through a complexity test, which is a useful predictor for how the wider reliance provisions in the proposed instrument will ultimately be scoped.

4. Practical recommendations

GRZAN recommends that clients adopt a dual-track, CE-first strategy: plan British supply of EU MDR and IVDR certified products on the basis of long-term recognition, while retaining but slowing down UKCA investment until the implementing legislation is settled. For MDD and AIMDD legacy products, arrange certificate renewal or an upgrade to MDR immediately against the current fixed point of 30 June 2028, and do not assume that long-term recognition has already been obtained, because the confirmation does not extend to those directives.

Across all external communication, the phrase policy confirmation must be kept clearly distinct from any claim that the law is already in force. Marketing materials, distributor contracts and investor documents should describe the indefinite recognition as a confirmed policy direction pending secondary legislation, since overstating its legal status could expose the company to claims of misrepresentation from partners who relied on it.

5. Verification checklist

• □ Products have been classified as MDR/IVDR (candidates for long-term recognition) or MDD/AIMDD/IVDD (still bound by fixed dates)
• □ Continued performance of the UKRP, MHRA registration and PMS obligations has been confirmed
• □ A monitoring mechanism for the implementing legislation has been established
• □ External materials clearly separate policy confirmation from enacted law
• □ The UKCA investment decision has been reassessed and documented

Regulatory information verified as of 29 October 2026.

• Appointment of a UK responsible person (UKRP) and support for signing the letter of authorisation
• MHRA registration (DORS): end-to-end filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee estimates
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) options
• Post-market surveillance (PMS) system build, PMSR/PSUR preparation and vigilance reporting
• Emergency handling of serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory change and compliance gap assessments

GRZAN supports manufacturers entering the United Kingdom with UKCA registration pathways and classification strategy, from first route analysis through to registration and post-market obligations. For a structured review of your product portfolio, contact info@grzanglobal.com.